


**Product Name** : BIIB021  
**Cat. No.** : PC-42459  
**CAS No.** : 848695-25-0  
**Molecular Formula** : C<sub>14</sub>H<sub>15</sub>ClN<sub>6</sub>O  
**Molecular Weight** : 318.7615  
**Target** : Heat Shock Protein (HSP)  
**Solubility** : DMSO: ≥ 45 mg/mL



## Biological Activity

BIIB021 (CNF2024) is a potent, selective, orally available **HSP90** inhibitor with K<sub>i</sub> of 1.7 nM for Hsp90α.

BIIB021 displays no significant activity against a broad panel of protein kinases, and Na<sup>+</sup>/K<sup>+</sup> ATPase.

BIIB021 induces the degradation of Hsp90 client proteins including HER-2, AKT, and Raf-1 and upregulates expression of Hsp70 and Hsp27 in tumor cells.

BIIB021 inhibits cell growth and induces cell death in cell lines from a variety of tumor types at nanomolar concentrations (IC<sub>50</sub>=60 nM in N87 cells).

BIIB021 exhibits antitumor effects in vivo.

## References

Kasibhatla SR, et al. *J Med Chem.* 2007 Jun 14;50(12):2767-78.

Lundgren K, et al. *Mol Cancer Ther.* 2009 Apr;8(4):921-9.

Böll B, et al. *Clin Cancer Res.* 2009 Aug 15;15(16):5108-16.

Gopalakrishnan R, et al. *Clin Cancer Res.* 2013 Sep 15;19(18):5016-26.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com